IRVINE, Calif., Jan. 6, 2006 (PRIMEZONE) -- "Biotech companies, in anticipation of a greatly expanding market based upon a large segment of the population hitting their elder years, are positioning and executing their business plans with some degree of fervor," said SmallCap Sentinel analyst, D.R. Clark. "Companies large and small want a piece of this perceived cash cow."
"MIV Therapeutics, Inc. (OTCBB:MIVT), for example, has been active in pursuing its initiatives in research and development while strengthening their business plan with financing and management additions," said Clark. "Clearly, the company wants to be 'ready' for successful entry to this burgeoning market."
MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on a broad range of other implantable medical devices. The company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the interaction with metal stents. The company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and exceptional biocompatibility, pursued by the science in the field of advanced implantable drug delivery systems.
An informational report, "The Silver Tsunami: Baby Boomers and Biotech Breakthroughs" is available free of charge at www.SmallCapSentinel.com
The report addresses issues related to emergent biotechnology potentially affecting companies including Johnson and Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), and Merck (NYSE:MRK).
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.